Victory Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.3K	Buy	15,161 +439	+3%	+$2.23K	﹤0.01%	2294
2025 Q4	$62.7K	Buy	14,722 +601	+4%	+$2.28K	﹤0.01%	2312
2025 Q3	$45K	Buy	14,121 +1,686	+14%	+$3.8K	﹤0.01%	2349
2025 Q2	$28.2K	Buy	+12,435	New	+$20K	﹤0.01%	2420
2021 Q4	–	Sell	-3,269,112	Closed	-$16.6M	–	2790
2021 Q3	$16.6M	Buy	3,269,112 +400,126	+14%	+$2.14M	0.02%	954
2021 Q2	$18.2M	Buy	2,868,986 +100,104	+4%	+$779K	0.02%	935
2021 Q1	$21.4M	Buy	2,768,882 +451,485	+19%	+$3.57M	0.02%	885
2020 Q4	$15.2M	Sell	2,317,397 -110,409	-5%	-$789K	0.02%	983
2020 Q3	$16.1M	Buy	2,427,806 +150,846	+7%	+$1.12M	0.02%	890
2020 Q2	$19M	Sell	2,276,960 -3,267,892	-59%	-$30.3M	0.03%	805
2020 Q1	$42.5M	Buy	5,544,852 +2,731,401	+97%	+$19M	0.04%	631
2019 Q4	$23.4M	Buy	2,813,451 +191,329	+7%	+$1.29M	0.03%	769
2019 Q3	$19.4M	Buy	2,622,122 +636,132	+32%	+$6.28M	0.02%	804
2019 Q2	$22.3M	Buy	1,985,990 +330,460	+20%	+$3.46M	0.04%	576
2019 Q1	$17.8M	Buy	1,655,530 +735,320	+80%	+$10.9M	0.04%	596
2018 Q4	$13.9M	Buy	920,210 +29,810	+3%	+$442K	0.03%	640
2018 Q3	$16.5M	Buy	890,400 +773,080	+659%	+$17.6M	0.03%	656
2018 Q2	$2.68M	Sell	117,320 -6,710	-5%	-$171K	0.01%	1010
2018 Q1	$3.53M	Buy	+124,030	New	+$3.54M	0.01%	903